Program
lepodisiran
Also written as “LY3819469”, “Lepodisiran” and “Lepodisiran Sodium”.
Its studies are mostly in Atherosclerosis · Liver Diseases · Renal Insufficiency, led by Eli Lilly.
Furthest: phase 3, since Feb 27, 20248 company-led studies, 3 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 83 open or running | phase 3since Feb 27, 2024 | Jun 1, 2021 | Mar 2027phase 1 · NCT07914738 |
- Named in Eli Lilly’s own pipeline as
Lepodisiran
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 1, 2021First study: phase 1 study in HealthyFirst studyNCT04914546 · 66 enrolled · United States, Singapore
- Oct 3, 2022Phase 2 study in Lipoprotein DisorderNCT05565742 · 320 enrolled · United States, Argentina, China and more
- Apr 24, 2023Phase 1 study in Renal InsufficiencyNCT05841277 · 26 enrolled · United States
- Jun 28, 2023Phase 1 study in HealthyNCT05932446 · 27 enrolled · Singapore
- Feb 27, 2024Phase 3 study in AtherosclerosisNCT06292013 · 17,300 enrolled · United States, Argentina, Australia and more
- Apr 1, 2025Phase 1 study in Liver DiseasesNCT06916078 · 30 enrolled · United States, Hungary
- May 22, 2026Phase 3 study in AtherosclerosisNCT07613294 · 252 planned · United States, Australia, Czechia and more
- Oct 29, 2026Phase 1 study in Lipoprotein(a)NCT07914738 · 66 planned
Ahead
- Mar 2027Primary completion: phase 1 study in Lipoprotein(a)NCT07914738
- Mar 2029Primary completion: phase 3 study in AtherosclerosisNCT06292013
- Dec 2029Primary completion: phase 3 study in AtherosclerosisNCT07613294
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07914738Lipoprotein(a) | 1 | Not yet recruiting | Mar 2027 | 66 |
| NCT07613294Atherosclerosis · United States, Australia, Czechia and more | 3 | Recruiting | Dec 2029 | 252 |
| NCT06916078Liver Diseases · United States, Hungary | 1 | Completed | Jul 13, 2026 | 30 |
| NCT06292013Atherosclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 2029 | 17,300 |
| NCT05932446Healthy · Singapore | 1 | Completed | Nov 7, 2023 | 27 |
| NCT05841277Renal Insufficiency · United States | 1 | Completed | Jan 9, 2024 | 26 |
| NCT05565742Lipoprotein Disorder · United States, Argentina, China and more | 2 | Completed | Oct 23, 2023 | 320 |
| NCT04914546Healthy · United States, Singapore | 1 | Completed | Nov 9, 2022 | 66 |
How it is read
Names in the registry
- “LY3819469”, 5 entries
- “Lepodisiran”, 2 entries
- “Lepodisiran Sodium”, 1 entry
Conditions, from the studies’ own filings
- Atherosclerosis, 2 studies
- Liver Diseases, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.